arrow
A

Ashique Rafique

Regeneron
H指数:33
被引数:7,214

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)

使用作用机制不同的FXI/FXIa抗体amrecibart(REGN9933A2)和cenvacibart(REGN7508Cat)进行抗凝

Blood
IF23.1
2026-06-150
OAAI
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
2023-06-212
OAAI
A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy
2023-04-041
PRE
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

通过CD3亲和力调节产生具有细胞因子释放和生物分布的分化特征的T细胞重定向双特异性抗体

2021-07-1364
OAAI
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
2020-06-2466
PREAI
Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop
2020-06-0953
OA
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

一类增强CD3-bispecific抗体抗肿瘤活性的共刺激CD28-bispecific抗体

2020-01-0894
OAAI
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation

需要用IL-4Rα 抗体dupilumab双重阻断IL-4和IL-13,以广泛抑制2型炎症

2020-01-03269
OAAI
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Science
IF45.8
2020-01-010
OAAI
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
2019-12-264
OAAI
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
2019-11-0164
OAAI
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells
2019-08-1916
OAAI